ArticleScientific reports2026
Inhibition of human histone lysine methyltransferases by a redox-labile S-adenosyl-L-homocysteine analog.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Methylation of lysine residues in histones by histone lysine methyltransferases is important for epigenetic gene regulation in humans. Histone lysine methyltransferases use S-adenosyl-L-methionine (SAM) as a co-substrate, producing the methylated lysine product and S-adenosyl-L-homocysteine (SAH) by-product. Inhibition of this class of epigenetic enzymes has potential for treatment of human diseases, including cancer. Here, we designed and developed a redox-labile S-adenosyl-L-homocysteine analog (SS-SAH) possessing a disulfide bond as a reversible inhibitor of biomedically important histone lysine methyltransferases GLP, G9a and SETD8. Combined enzyme assays, docking studies and molecular dynamics simulations provide insight into inhibition and binding mode of the redox-labile SS-SAH, and demonstrate that the inhibitory activity of SS-SAH could be deactivated by cleavage of the disulfide bond upon the addition of a reductive agent. Overall, this work highlights a utility of unique redox-labile inhibitors of epigenetic enzymes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.